Intestinal Microbiota-A Promising Target for Antiviral Therapy?
- PMID: 34054866
- PMCID: PMC8149780
- DOI: 10.3389/fimmu.2021.676232
Intestinal Microbiota-A Promising Target for Antiviral Therapy?
Abstract
The intestinal microbiota is thought to be an important biological barrier against enteric pathogens. Its depletion, however, also has curative effects against some viral infections, suggesting that different components of the intestinal microbiota can play both promoting and inhibitory roles depending on the type of viral infection. The two primary mechanisms by which the microbiota facilitates or inhibits viral invasion involve participation in the innate and adaptive immune responses and direct or indirect interaction with the virus, during which the abundance and composition of the intestinal microbiota might be changed by the virus. Oral administration of probiotics, faecal microbiota transplantation (FMT), and antibiotics are major therapeutic strategies for regulating intestinal microbiota balance. However, these three methods have shown limited curative effects in clinical trials. Therefore, the intestinal microbiota might represent a new and promising supplementary antiviral therapeutic target, and more efficient and safer methods for regulating the microbiota require deeper investigation. This review summarizes the latest research on the relationship among the intestinal microbiota, anti-viral immunity and viruses and the most commonly used methods for regulating the intestinal microbiota with the goal of providing new insight into the antiviral effects of the gut microbiota.
Keywords: COVID-19; SARS-CoV-2; immunity; intestinal microbiota; virus.
Copyright © 2021 Yang, Yang, He, Zhu, Liu, Xu and Zhao.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
The microbiota-mediated dietary and nutritional interventions for COVID-19.Clin Immunol. 2021 May;226:108725. doi: 10.1016/j.clim.2021.108725. Epub 2021 Apr 9. Clin Immunol. 2021. PMID: 33845194 Free PMC article. Review.
-
Probiotics in Medicine: A Long Debate.Front Immunol. 2020 Sep 25;11:2192. doi: 10.3389/fimmu.2020.02192. eCollection 2020. Front Immunol. 2020. PMID: 33072084 Free PMC article. Review.
-
Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.Int J Mol Sci. 2021 May 6;22(9):4942. doi: 10.3390/ijms22094942. Int J Mol Sci. 2021. PMID: 34066560 Free PMC article. Review.
-
Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.Front Immunol. 2018 Sep 10;9:2042. doi: 10.3389/fimmu.2018.02042. eCollection 2018. Front Immunol. 2018. PMID: 30250472 Free PMC article. Review.
-
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.Pharmacol Ther. 2015 May;149:191-212. doi: 10.1016/j.pharmthera.2014.12.006. Epub 2015 Jan 3. Pharmacol Ther. 2015. PMID: 25561343 Review.
Cited by
-
The evolution of the antimicrobial peptide database over 18 years: Milestones and new features.Protein Sci. 2022 Jan;31(1):92-106. doi: 10.1002/pro.4185. Epub 2021 Sep 24. Protein Sci. 2022. PMID: 34529321 Free PMC article. Review.
-
Virus-host interaction mechanisms in interferon therapy for hepatitis B virus infection: recent advances.Front Immunol. 2025 Jun 27;16:1603544. doi: 10.3389/fimmu.2025.1603544. eCollection 2025. Front Immunol. 2025. PMID: 40655152 Free PMC article. Review.
-
Mini-review: microbiota have potential to prevent PEDV infection by improved intestinal barrier.Front Immunol. 2023 Jul 12;14:1230937. doi: 10.3389/fimmu.2023.1230937. eCollection 2023. Front Immunol. 2023. PMID: 37503350 Free PMC article. Review.
-
A novel hypothesis for COVID-19 pathogenesis: Retinol depletion and retinoid signaling disorder.Cell Signal. 2021 Nov;87:110121. doi: 10.1016/j.cellsig.2021.110121. Epub 2021 Aug 23. Cell Signal. 2021. PMID: 34438017 Free PMC article.
-
Cephalosporins-induced intestinal dysbiosis exacerbated pulmonary endothelial barrier disruption in streptococcus pneumoniae-infected mice.Front Cell Infect Microbiol. 2022 Aug 24;12:997368. doi: 10.3389/fcimb.2022.997368. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36093187 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous